UBS Group’s NeoGenomics NEO Stock Holding History

UBS Group’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.6M	Buy	+2,233,150	New	+$21.5M	﹤0.01%	2180
2024 Q2	–	Sell	-46,100	Closed	-$725K	–	9912
2024 Q1	$725K	Buy	+46,100	New	+$712K	﹤0.01%	4878

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

UBS Group's NEO Position: Q2 2026 in Review

UBS Group increased its NeoGenomics (NEO) stake by 202% in Q2 2026, buying an estimated $3.71M and bringing the position to 575,166 shares worth $8.39M. The position accounts for ﹤0.01% of the portfolio, ranked #3636.

UBS Group first reported a position in NEO in Q4 2014 and has held it in 47 quarters since. 267 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

UBS Group held 575,166 shares of NeoGenomics worth $8.39M as of Q2 2026.
UBS Group bought 384,710 NeoGenomics shares in Q2 2026, an estimated $3.71M.
NeoGenomics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3636 holding.
UBS Group first reported a position in NeoGenomics in Q4 2014 and has held it in 47 quarters since.
267 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.